HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast.
Bièche I, Coussy F, El-Botty R, Vacher S, Château-Joubert S, Dahmani A, Montaudon E, Reyes C, Gentien D, Reyal F, Ricci F, Nicolas A, Marchio C, Vincent-Salomon A, Laé M, Marangoni E.
Bièche I, et al. Among authors: lae m.
J Hematol Oncol. 2021 Sep 8;14(1):143. doi: 10.1186/s13045-021-01158-3.
J Hematol Oncol. 2021.
PMID: 34496925
Free PMC article.